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Allergic airway disease is a growing problem throughout the world. 1 There is a dramatic increase in the prevalence of allergic diseases in the last four decades. Respiratory allergies have become the most common chronic disease among adolescent and young adults. 2, 3 There are updated treatment approaches for asthma and allergic rhinitis such as training of the patient, protecting from allergens, pharmacotherapy, and allergen specific immunotherapy (ASI). 4, 5 ASI has been applied approximately for the last 100 years and it is the unique treatment method which can change the natural course of the disease in case of respiratory allergies. It has been shown that the immunological mechanism of action increases the immune tolerance. 6 ASI is mainly prescribed and managed by allergists. But, the presence of allergist seems to be largely insufficient in this specific field of immunotherapy and knowledge about ASI is low overall and varies widely by country: in Europe, 30% had never heard of ASI. 7 The aim of this study is to determine knowledge levels related to allergen specific immunotherapy (ASI) and perspectives of parents whose children were diagnosed with asthma and/or allergic rhinitis with positive skin prick test in our pediatric allergy and immunology outpatient clinic.
Material and Methods
The study was conducted between September 2014 and December 2015 in pediatric allergy and immunology outpatient clinic. Before conducting the study, the permission was obtained from the Non-invasive Clinical Ethics Committee (2014/09-21). The survey was composed of 7 questions related to the demographical and socio-cultural characteristics of parents, 8 questions related to the knowledge levels of parents about ASI, and 2 questions related to the views of parents about ASI. We included the parents of children who have been followed up at least for the last three years in the pediatric allergy and immunology outpatient clinic with asthma and/or allergic rhinitis and who have skin test positivity for at least one of the inhalant allergens. Asthma and allergic rhinitis were diagnosed in line with the international guidelines. 5, 8 Consents of families whose children met the criteria were obtained and the surveys were applied to them. The data of the study were recorded in the SPSS for Windows V. 16 17 .8% of them were diagnosed only with allergic rhinitis (n=35), and 39.6% of them were diagnosed with both asthma and allergic rhinitis (n=79) ( Table I ).
The frequency of parents stating that they were aware of the ASI application for allergic disease treatment was 42.6%. Parents reached this information respectively from pediatric allergy specialists (25.5%), relatives and friends (17.8%), media (television, internet, newspapers, etc), and pediatricians (8.2%).
Twenty-three percent of the parents did not have an atopy background whereas at least one of the 55% of the family members (mothers, fathers and/or siblings) had an atopy history. Furthermore, 22% of the other relatives also had a history of an atopy. Individuals with an atopy background in the family had higher Table II and III, respectively.
Discussion
Allergic airway diseases such as allergic asthma and allergic rhinitis are growing problems throughout the world. 1 Both of these diseases lead to deterioration of sleeping habits and decrease the quality of work and school life. 9, 10 Treatment approaches for asthma and allergic rhinitis include: training of the patient, protecting from allergens, pharmacotherapy, and allergen specific immunotherapy (ASI). 5 Even though it is possible to protect the patient from allergens, it is hard to control the symptoms in allergic respiratory diseases in daily life by only protecting the patient from allergens. There are cheap and safe drugs in the treatment of allergic symptoms. However, 57% of the patients can experience side effects of these drugs and sufficient symptom control may not be ensured. 11, 12 Furthermore, pharmacotherapy may not have an effect on the course of the disease and it is required to have the drugs as long as the patients have the symptoms throughout their life.
ASI was first applied by Leonard Noon 104 years ago by administering pollen extracts to the patient subcutaneously. It is a unique and potential therapy for allergic diseases by changing the natural course of the disease, preventing the asthma and new allergen sensitivity, and increasing the allergen specific immune tolerance. 13 ASI has been applied for respiratory diseases such as allergic asthma and allergic rhinitis, venom allergies, and recently for food allergy and atopic dermatitis.
ASI was primarily applied subcutaneously and its use was limited because of its fatal side effects in 1980s. Researchers have tried to find safer routes of drug administration. 14 Sublingual ASI has been increasingly applied in various European countries in the last 25 years because of low rates of severe side effects and ease of its use. 15 Some local and systemic side effects of ASI have been reported. Local reactions are observed both subcutaneous ASI (erythema, itching and swelling at the injection site) and sublingual ASI (oropharyngeal itching, edema). These reactions can be observed in the 82% of the patients who receive subcutaneous ASI and 75% of the patients who receive sublingual ASI. 16, 17 The side effect risk is prominently lower in sublingual ASI when compared to subcutaneous ASI. 17 The effectiveness of the ASI has been shown in important clinical studies and meta-analyses. However, it has a limited use and it is estimated that its frequency of use is less than 10% in allergic rhinitis and asthma patients throughout the world 13 . There are some reasons why ASI is rarely used: 1) there is a lack of consensus about its efficiency and safety, 2) there is a the lack of data about its cost effectiveness, 3) it has the long duration of treatment and 4) there is a lack of awareness of the ASI treatment in the general population and among physicians who did not receive allergy and immunology education. 18 In general, ASI is mainly prescribed and managed by allergist.
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In some European countries, allergology is not recognized or has been discontinued as a separate medical specialty, and allergic patients are often treated by other specialists. Low usage and knowledge in some countries could potentially be attributed to limited patient access to the specialist physicians likely to prescribe (and provide information on) this treatment. In ALL (Allergy Living and Learning) study, when patients were asked about their knowledge of ASI, 30% had never heard of it, less than half (47%) knew something or a little about it, and only 23% knew it well or really well. These values varied widely across Europe, with 52% of patients in Sweden knowing nothing about ASI as compared with 10% of patients in Italy. Only 7% of patients in the UK knew this treatment well or really well, as compared with 44% in Germany. However, the general level of interest in ASI was more consistent between countries, with 30% of patients stating that they were interested in ASI. 7 Our present study is the first study in Turkey which evaluates the knowledge levels related to allergen specific immunotherapy (ASI) and perspectives of parents whose children were diagnosed with asthma and/or allergic rhinitis. Our study was conducted in Izmir which is one of the most developed cities in Turkey and which is one of the cities in which the literacy rate is quite high. According to our findings, the awareness of ASI is quite high in our patient population (42.6%).
Allergic diseases and their treatments have recently been mentioned via information programs (such as public spots and television programs related to medical issues, etc.) and articles in media such as television, internet, and newspaper. This leads to raised awareness of individuals about ASI. There is no such study in which it is shown how parents of pediatric patients with allergic rhinitis and asthma can reach the information about ASI and the opinions of these families about ASI have also not been given in any of the studies. In our country, ASI was managed by pediatric allergy specialist in pediatric patients with allergic rhinitis and/or asthma. In this study, it has been concluded that most of the parents reached the information about ASI via pediatric allergy specialist (25.5%). It could be because it is easy to directly reach pediatric allergy specialists in Izmir, Turkey.
There is a significant relationship between having knowledge about the ASI in the treatment of allergic diseases and the presence of atopy in the family, the education level of mothers, and monthly per capita income in the family. The awareness of ASI application that is used in allergic diseases is high in families when there is an atopy background in at least one individual of the family members (motherfather or siblings), when the education level of the mother is high, and when the monthly per capita income is high. In our study, the awareness of ASI that is used in allergic diseases is high and the information about ASI is less, as estimated. It was detected that only 10.6% of the families have proper knowledge about the subcutaneous and sublingual application of the ASI, 4.5% of them were aware of that sublingual ASI is safer, 9.5% of them knew that there can be fatal side effects during the ASI treatment, 10.6% of them were aware of that ASI prevents the asthma in allergic rhinitis patients, and 34.9% of them knew that ASI decreases the drug use requirements.
In our study, we firstly evaluated the parents' opinions related to subcutaneous and sublingual ASI. After informing parents about subcutaneous and sublingual ASI; 88.7% of them preferred sublingual ASI because it is easy to apply and its severe side effect incidence is low.
Consequently, the majority of our patient population has the knowledge of ASI that is applied in allergic diseases and they reached this information mostly via pediatric allergy specialist. The frequency of ASI use in allergic diseases is low both in the world as well as in Turkey. It is thought that allergists and media outlets have important roles in explaining the benefits and efficiency of ASI application which can change the course of the disease. Our study is important because it mentions the views of parents whose children were diagnosed with allergic rhinitis and/or asthma with positive skin prick test. Furthermore, how these parents reached the information about ASI and their opinions related to subcutaneous and sublingual ASI are also firstly evaluated in our study.
